Top Stories Crispr Therapeutics Stock Surges 65% Yet Remains Undervalued UPDATE: Crispr Therapeutics (CRSP) is making headlines as its stock rockets up by 65% year-to-date through September 30, 2025. However, despite this impressive surge,... Editorial8 hours ago